Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-6837 · 1 trial · 1 indication
The following events will be considered a DLT unless clearly due to underlying disease or extraneous causes: Grade 4 neutropenia lasting \>7 days; Grade 3 or higher thrombocytopenia associated with clinically significant bleeding, regardless of duration; All Grade 3 or higher nonhematologic toxicities (with exceptions); Any abnormality that results in a drug induced liver injury; Febrile neutropenia Grade 3 or 4; Prolonged delay (\>2 weeks) in initiating treatment after the first 21 days due to intervention-related toxicity; Any intervention-related toxicity that causes the participant to discontinue intervention during the first 21 days; Grade 5 toxicity. The number of participants who experience a DLT will be presented.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Arm | Type | Description |
|---|---|---|
| Arm 1: MK-6837 Monotherapy | EXPERIMENTAL | Participants receive escalating doses of MK-6837 via intravenous (IV) infusion once every 3 weeks (Q3W) (Day 1 of every 21-day cycle) until progressive disease or discontinuation. |
| Arm 2: MK-6837 + Pembrolizumab Combination Therapy | EXPERIMENTAL | Participants receive escalating doses of MK-6837 via IV infusion Q3W (Day 1 of every 21-day cycle) until progressive disease or discontinuation PLUS 200mg of pembrolizumab via IV infusion Q3W (Day 1 of every 21-day cycle) for up to 35 administrations (up to \~2 years). |
| Name | Type | Description |
|---|---|---|
| MK-6837 | BIOLOGICAL | IV Infusion |
| Pembrolizumab | BIOLOGICAL | IV Infusion |
| Rescue Medications | DRUG | Antihistamine, H2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) administered per product label prior to MK-6837. |
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Histologically or cytologically confirmed solid tumor by pathology report that is advanced or metastatic * Human Immunodeficiency Virus (HIV)-infected participants must have well controlled HIV on Antir...
MK-6837 is an investigational monoclonal antibody being studied for the treatment of neoplasm metastasis, specifically in participants with advanced or metastatic solid tumors. It is being evaluated as a monotherapy and in combination therapy. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
MK-6837 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational monoclonal antibody in patients with advanced or metastatic solid tumors.
MK-6837 is in Phase 1 clinical development. The drug is being studied in a Phase 1 trial that has been completed, with 40 participants enrolled. As an investigational drug, MK-6837 has not yet received regulatory approval and is still undergoing clinical evaluation for the treatment of neoplasm metastasis.
MK-6837 has been studied in one clinical trial with the identifier NCT06460961, titled "A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)." This Phase 1 trial enrolled 40 participants and was conducted in the United States, Australia, Canada, and Israel.
MK-6837 is a monoclonal antibody, a type of biologic drug designed to bind to specific targets involved in disease. However, the specific molecular target of MK-6837 has not been disclosed in available information. The drug is being investigated for its potential to treat advanced or metastatic solid tumors.